Genmab — Januar 2026

[Plimsoller]

*some

[StockBull]

Vi har nu brudt ned og ud af den kanal, jeg tidligere linkede til.
Jeg opfatter det ikke som særligt alarmende endnu, men et dybere brud under 2000 ville absolut være negativt.
Med al den frygt der præger markedet lige nu (Trump, etc.), regner jeg med at supplere med lidt flere gennemsnitskøb i området omkring 2000. Har ikke kigget på FA så ret TA vurdering som jeg selv handler efter.

[E_L]

JP Morgan remains Neutral | Price Target Dkr 2,050 https://x.com/_ShahKruti/status/2013574730918527445

[E_L]

Ram Selvaraju
H.C. Wainwright
Buy $39.00 Reiterated 20-1-26 (from $40
i think)

[gentogen]

Regarding the China Sub phase 3 in R/R DLBCL, the reason for splitting may be that the China part started in 2022-10, wheres as the main study started in 2021-1 (so we may need to wait a bit longer for results, I suppose)

[E_L]

that's towards the end of the covid pandemic isn't it... could be really interesting to see if there is a difference. Also they may have other practice regime used for follow up therapies

[E_L]

the whole trial went 'Active, not recruiting' already in june 23 and after the split both had the same Primary Completion date, Oct25, so we may not have to wait that long for the China part. Actually, maybe it is already included, it is a sub-study of DLBCL-1 ?

[Pensionisten]

Føj......(-:

[w]

genmab classic

[Vitus]

Massakren er en realitet

[gentogen]

The number of patients in the recent data shows that China is not included so far

[Pensionisten]

Der blev lidt tavst på chatten ! Er det Over and out, and RIP?

[concillado]

Man skulle da lige have taget lidt gevinsthjemtagning i 2250

[gdn55]

Hvorfor det

[concillado]

...inden Trump-babyen gik i gang igen. "Kun" 3 år tilbage med hans rablende infantile vanvid xD

[E_L]

ok gentogen , than we have something to look forward to

[ProinvestorNEWS]

DNB Carnegie løfter Genmabs anbefaling til "køb" og skruer pænt op for kursmålet https://proinvestor.com/investornyt/1405261/dnb-carnegie-lofter-genmabs-anbefaling-til-kob-og-skruer-paent-op-for-kursmalet

[E_L]

hey gentogen , thinking again on that China part of the trial ; too many Asian patients in the trial was where Roche/Genentech got in trouble with Columvi wasn't it; they got a Complete Response Letter from the FDA for the reason that OS was much better in Asian patients compared to non-Asian patients so FDA determined OS was not proven for Americans

[E_L]

and that was Columvi chemo combination and they
still have the accelerated approval

[E_L]

• 4Q DARZALEX REVENUE $3.90B, EST. $3.75B